AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06647199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the bleeding index (BI)
Description: Peri-implant tissue changes as bleeding score was assessed employing the bleeding index (BI) . Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD).
Study NCT06647199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simpliﬁed gingival index(GI),
Description: Peri-implant soft tissue changes as regards gingival scores was assessed simpliﬁed gingival index(GI). Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD
Study NCT02168478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-Synalar Cream
Description: Approximately 0.2 g of test material is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
Study NCT02168478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Lauryl Sulfate Aqueous Solution (0.40%)
Description: Approximately 0.2 ml of the positive , 0.40% aqueous solution of sodium lauryl sulfate is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
Study NCT02168478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
Study NCT03793322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine-Green(ICG)
Description: ICG was administered intravenously 24 hours before the operation , or directly into the portal vein branches supplying the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
Study NCT01174498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerbomed t-VNS® transcutaneous stimulation
Description: Subjects experience a transcutaneous, electrical, vagal stimulation with the t-VNS device.
Study NCT01174498 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: t-VNS Sham stimulation
Description: t-VNS Sham stimulation
Study NCT01212484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
Study NCT01212484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
Study NCT04184856 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: (Imaging while) performing reward related tasks.
Study NCT03830515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microMend
Description: Wound closure product consisting of tan array of tiny metal Microstaples affixed to adhesive backing. The device is the size and shape of a butterfly closure and intended for closure of skin wounds.
Study NCT04087070 — intervention group
Intervention type: DEVICE
Intervention: Biosignal measurements
Description: Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~1. PAT(time between R peak of ECG and beginning of the pulse of PPG)~2. PEP(time between R peak of ECG and peak of accelerometer signal)~3. PTT(PAT-PEP)
Study NCT01267058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine
Description: Intramuscular, single dose
Study NCT03039491 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13 valent conjugated pneumococcal vaccine
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197
Study NCT03039491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent conjugated pneumococcal vaccine
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197
Study NCT02106702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigator enhanced case-management
Description: Patient navigators are non-clinical, paraprofessional peers who are HIV-infected and have lifetime histories of detention and substance abuse. Working with the patient, they facilitate adherence to a comprehensive care plan designed to address clients' multiple risks and needs. Patients have access to Navigator services for one year after study enrollment.
Study NCT02106702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forensic AIDS Project
Description: The Forensics AIDS Project provides primary care to HIV-infected detainees, as well as up to 90 post-release case-management services which include discharge planning.
Study NCT03182634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study NCT03182634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Study NCT03182634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Study NCT03182634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Study NCT03182634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Study NCT02847338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.
Study NCT02847338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.~Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm.
Study NCT02847338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
Study NCT02847338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlortalidone
Description: Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.
Study NCT02827643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement
Description: Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
Study NCT02827643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TDF/3TC or FTC/EFV
Description: arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
Study NCT04526574 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
Description: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
Study NCT04526574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Normal saline for injection
Study NCT04526574 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Seasonal inactivated influenza vaccine (SIIV)
Study NCT04205461 — intervention group
Intervention type: PROCEDURE
Intervention: Programmed ventricular stimulation
Description: Programmed ventricular stimulation before pulmonary valve replacement. Voltage and activation mapping of right ventricle in a subset of patients.
Study NCT03102697 — intervention group
Intervention type: DEVICE
Intervention: Air-filled Intragastric balloon
Description: Weight loss system that consists of an air balloon that occupies space in the stomach, thus reducing the gastric capacity and leaving less volume for food.
Study NCT03848806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAT1
Description: During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Study NCT03848806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Study NCT00000448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
Study NCT00000448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
Study NCT02491125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soluble wheat bran fibre
Description: 12 weeks daily intake of 15g of soluble wheat bran fibre
Study NCT02491125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks daily intake of 15g of maltodextrin
Study NCT05158686 — intervention group
Intervention type: DEVICE
Intervention: Paclitaxel-coated Balloon dilation angioplasty
Description: Paclitaxel-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization
Study NCT05158686 — intervention group
Intervention type: DEVICE
Intervention: Non-coated Balloon dilation angioplasty
Description: Non-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization
Study NCT02510313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugira Muryango
Description: Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning.
Study NCT04289090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane Inhalant Product
Description: This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
Study NCT04289090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 10 MG/ML
Description: This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
Study NCT03646487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic LP299v 10x10 colony forming units in capsule form
Description: Daily lactobacillus plantarum (LP299v) 10x10 colony forming units in capsule form
Study NCT03646487 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in capsule form
Description: Daily placebo in capsule form
Study NCT01831505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them
Study NCT02636556 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiation
Description: The patients receive chemotherapy concurrent with Radiotherapy. The prescription dose is 60Gy in 30 fractions in 6 weeks.The chemotherapy regimen is cisplatin (25mg/m2,iv drip,d1-3) and etoposide (75mg/m2,iv drip,d1-3),q4w\*4.
Study NCT01416155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Study NCT01622725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placing the resorbable mesh
Description: Surgery for primary and secondary ventral hernia repair with placing of resorbable mesh.
Study NCT01622725 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-resorbable synthetic mesh.
Description: Surgery for primary and secondary ventral hernia repair with placing of non-resorbable synthetic mesh.
Study NCT04470284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: SMBP with mobile App based feed-back algorithm. The App based feed-back algorithm will remind the patients of taking drug to improve BP control and drug compliance.
Study NCT04470284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard SMBP
Description: Standard treatment (SMBP-alone)
Study NCT01683422 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton, Gemcitabine, Erlotinib, Capecitabine
Description: Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.~Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles.
Study NCT01683422 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Study NCT01891318 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiosurgery
Description: Undergo radiosurgery
Study NCT01891318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection
Study NCT01891318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01971632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone & naloxone combination, prolonged release
Study NCT03575689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doyle Splint
Description: Using Doyle splints following septoplasty is the standard of care and may help with stability of the septum in the immediate post op period. owever these splints are associated with morbidity in the post-op period. The quilting technique was developed to prevent complications and stabilize the septum. This study examines the efficacy of these splints in stabilizing the septum and preventing complications after septoplasty
Study NCT02214823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES-Cycling
Study NCT02214823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
Study NCT01971632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo oxycodone / naloxone
Study NCT01923337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT01923337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Given PO
Study NCT02590757 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV-NAVA
Description: Non-invasive neurally adjusted ventilatory assist
Study NCT02590757 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N-CPAP
Description: Nasal-continuous positive airway pressure
Study NCT02101333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: intravenous injection 8 mg/kg, monthly during 6 months
Study NCT01601002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine 7.5 to 45 mg/day, once daily, 12 weeks open label
Study NCT05691764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Description: Cyclosporin was administered intravenously with the dose of 3 mg/ kg body weight
Study NCT05691764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: Performed by inflating pressure cuff on the extremity 30 mmHg higher than systolic blood pressure of the patient for 5x5 minutes with 5 minutes reperfusion interval
Study NCT00738166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic or conventional diet
Description: 12 days on fully controlled organic 1 diet, organic 2 diet and conventional diet
Study NCT05691764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo
Study NCT01279174 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional physiotherapy
Description: Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
Study NCT01279174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
Study NCT00558051 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC-based vaccine
Description: Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 4 intradermal injections once a day for 4 days.
Study NCT00558051 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC-based vaccine
Description: Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 1 intranodal injection.
Study NCT00558051 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC-based vaccine
Description: Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of a 4-day intralymphatic infusion.